ProCE Banner Activity

TOPAZ-1: Patient-Reported Outcomes From the Phase III Placebo-Controlled Trial of Durvalumab + Gemcitabine + Cisplatin for Advanced Biliary Tract Cancer

Slideset Download
Conference Coverage
In addition to a previously reported overall survival benefit, durvalumab + gemcitabine/cisplatin was associated with a trend toward longer time to deterioration in global health status/quality of life for patients with advanced biliary tract cancer vs placebo + gemcitabine/cisplatin.

Released: June 09, 2022

Expiration: June 08, 2023

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

BMS

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp

Novartis Pharmaceuticals Corporation

Seagen and Genmab